BMS' kidney transplant drug, Nulojix, granted European approval
This article was originally published in Scrip
Executive Summary
Just days after US approval, Bristol-Myers Squibb's Nulojix (belatacept) has been granted marketing authorisation in Europe for the prophylaxis of graft rejection in adult patients receiving a kidney transplant when used in combination with corticosteroids and a mycophenolic acid.